Nobiletin Inhibits Cell Growth, Migration and Invasion, and Enhances the Anti-Cancer Effect of Gemcitabine on Pancreatic Cancer Cells

Xiang Ren1*, Yuran Ma1*, Xiao Wang1, Xuetao Xu1,2, Panpan Wu1, Wenfeng Liu1,2, Kun Zhang2, Susan Goodin3, Dongli Li2,3, and Xi Zheng3,4

Abstract

Natural products are very promising adjuvants with a variety of biological activities. Nobiletin, a citrus polymethoxyflavone, has been shown to exert an anticancer effect in various cell lines. In this study, we investigated the effects of nobiletin on cell viability, sphere formation, migration and invasion of pancreatic cancer cells, and the underlying mechanisms. Our results demonstrate that nobiletin significantly inhibited PANC-1 cell migration and invasion, and these effects were associated with downregulation of MMP-2. We also found that nobiletin, in a low concentration, exhibited a strong inhibitory effect on sphere formation. The potential molecular mechanisms were related to significant downregulation of p-mTOR and p-STAT3. Furthermore, we found that nobiletin combined with gemcitabine synergistically inhibited PANC-1 cell viability and sphere formation. The underlying mechanisms of the synergistic inhibition on growth were associated with decreases in p-STAT3 expression. Overall, our results suggest that nobiletin may be a promising candidate for pancreatic cancer adjuvant treatment.

Keywords

nobiletin, gemcitabine, STAT3, mTOR, pancreatic cancer

Received: February 19th, 2021; Accepted: February 23rd, 2021.

Pancreatic cancer is one of the most aggressive and lethal cancers worldwide. It was estimated that this disease caused more than 45 000 deaths in the United States. In contrast to other cancer types, pancreatic cancer has the lowest 5-year relative survival rate of only 9%. Gemcitabine, a nucleoside analog, is the first-line FDA-approved chemotherapy drug for treating pancreatic cancer. However, gemcitabine has a low response rate with limited progression-free survival in patients. Chemoresistance and toxic side effects also limit the clinical success of gemcitabine. Hence, it is urgent to develop novel preventive and/or therapeutic approaches for better control and management of this aggressive malignant tumor disease.

Compounds derived from natural sources have been shown to inhibit signaling pathways important for cancer cell growth and survival. Polymethoxyflavones (PMFs) are mainly derived from the Citrus species (family Rutaceae), especially from C. sinensis and C. reticulata. Some studies have demonstrated a wide range of biological activities of PMFs, such as anti-inflammatory, anti-cancer, and preventing obesity effects. Nobiletin (Figure 1(A)), one of the widely known citrus polymethoxyflavones, has anti-proliferative, anti-angiogenesis, and apoptotic effects in various cancer types, including pancreatic cancer. Moreover, nobiletin exhibits a great ability for enhancing the efficacy of anticancer agents. One group of researchers demonstrated that nobiletin enhances the efficacy of paclitaxel in ABCB1 overexpressing cancer cells by inhibiting the AKT/ERK/Nrf2 pathway, and studies conducted by another group of researchers indicated

1School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, Guangdong Province, China
2International Healthcare Innovation Institute, Jiangmen, Guangdong Province, China
3Rutgers Cancer Institute of New Jersey, New Brunswick, USA
4Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
5Drs Xiang Ren and Yuran Ma contributed equally to the work.

Corresponding Author:
Xi Zheng, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Email: xizheng@ pharmacy.rutgers.edu
that nobiletin, in combination with atorvastatin, acts synergistically to inhibit colon carcinogenesis.\textsuperscript{21} However, the effect of nobiletin in combination with gemcitabine on pancreatic cancer cells has not been studied.

In the present study, we aimed to determine the potential effect of nobiletin on pancreatic cancer in vitro and reveal the possible molecular mechanisms. Our data demonstrated that nobiletin effectively inhibited pancreatic cancer cell survival, sphere formation, migration and invasion. The effects of nobiletin on pancreatic cancer cells were associated with decreases in phosphorylated mTOR (p-mTOR) and p-STAT3 phosphorylation. Moreover, the results of our experiments indicate that nobiletin enhances the effect of gemcitabine on pancreatic cancer cells. The results of our present study suggest that nobiletin may be a promising candidate for future development of pancreatic cancer adjuvant treatment.

**Methods**

**Cell Culture and Reagents**

PANC-1 and MIA PaCa-2 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Nobiletin was acquired from Dalian Meilun Biotechnology Co, Ltd (MB6570-S), and gemcitabine from LC Laboratories, USA. DMEM culture medium, penicillin/streptomycin, L-glutamine, and fetal bovine serum (FBS) were obtained from Gibco (Grand Island, NY). PANC-1 cells were maintained in a DMEM culture medium containing 10% FBS that was supplemented with penicillin (100 units/mL)-streptomycin (100 µg/mL) and L-glutamine (300 µg/mL). Cultured cells were grown at 37 °C in a humidified atmosphere of 5% CO\textsubscript{2} and were passaged twice a week.

**Cell Viability Assay**

PANC-1 and MIA PaCa-2 cells were seeded on 96-well plates at a density of $5 \times 10^5$ per well and incubated at 37 °C for 24 hours. The cells were then treated with various concentrations of nobiletin (0, 120 µM) for 72 hours. After treatment, 100 µL of MTT solution (0.5 mg/mL in DMEM medium) was added to each of the wells and incubated at 37 °C for 4 hours. After careful remove of the medium, 100 µL DMSO was added to each well. The absorbance was recorded on a microplate reader at 490 nm.

**Wound-Healing Assays**

Cell migration ability was assessed using a wound-healing assay. In brief, cells were seeded at $1 \times 10^5$ cells/well in 6-well plates. After 24 hours, when the cells were 95% to 100% confluent, media was removed and the cell surface was scratched using a sterile 200 µL pipette tip. Floating cells were removed by washing twice with PBS. Cultivation was subsequently continued for 24 hours and 48 hours in 1% FBS medium. The cells were treated with different concentrations of nobiletin.

**Transwell Analysis**

Transwell invasion assay was performed in a 24-well transwell unit (8 µm pore size) which was coated with Matrigel matrix (Corning, USA) as described by the manufacturer. Cells were seeded at $4 \times 10^5$ cells/well in serum-free DMEM media (200 µL) in the top chamber, and treated with different concentrations of nobiletin for 24 hours. The lower chamber was filled with 800 µL DMEM supplemented with 20% FBS. The ability of migration was assessed in chambers without matrix. After incubation at 37 °C for 24 hours, cells were fixed with methanol and stained with 0.1% crystal violet. The number of cells was determined by counting randomly on each membrane.

**Western Blot**

PANC-1 cells were seeded at a density of $1 \times 10^5$ cells in 100 mm culture dishes and treated with nobiletin for 24 hours. After treatment, the cell lysates were prepared as described earlier. Proteins were subjected to sodium dodecyl sulfate
Figure 1. Effect of nobiletin on cell viability in PANC-1 and MIA PaCa-2 cells. (A) Chemical structures of nobiletin. (B) PANC-1 and MIA PaCa-2 cells were treated with nobiletin for 24 hours, 48 hours, and 72 hours, and cell viability was measured using MTT assay. (C) Cell morphology under a microscope treated with nobiletin for 72 hours. Effect of nobiletin on sphere formation in PANC-1 cells and MIA PaCa-2 cells. (D-E) Tumor sphere size and sphere formation rate were shown after treated with nobiletin for 14 days. Data shown are mean ± SEM, n = 3, ***P < 0.001 compared with the control group.
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. After blocking nonspecific binding sites with blocking buffer, the membrane was incubated overnight at 4 °C with primary antibodies. β-Actin was used as a loading control. Following removal of the primary antibody, the membrane was washed 3 times with TBS (PBS containing 0.05% tween 20) buffer at room temperature and then incubated with fluorochrome conjugated secondary antibody. The membrane was then washed with TBS, 3 times. The final detection was carried out using Pierce™ ECL Western Blotting Substrate (Thermo, USA).

Sphere Formation Assay

For sphere formation assay, PANC-1 and MIA PaCa-2 cells were dissociated and passed through a 70 μm filter (BD, Falcon) to produce single cell suspensions. Then, 3000 cells/well were seeded and grown in a 24-well plate with Keratinocyte serum-free medium, supplemented with 5 ng/mL epidermal growth factor (EGF) and 50 μg/mL bovine pituitary extract (BPE) (both from Gibco, USA) for 14 days. The cells were treated with different concentrations of nobiletin. After that, the number of spheres was counted under a light microscope (Nikon Optiphot, Tokyo, Japan).

Transfection With STAT3 and mTOR siRNA

STAT3 siRNA, mTOR siRNA and scrambled negative control siRNA were from Cell Signaling Tech. PANC-1 cells were seeded in 6-well plates and incubated for 24 hours to allow adherence of cells. SiRNA was transfected into the cells using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. The final concentration of siRNA was 100 nM. After 48 hours, the cells were harvested for expression assay or treating with nobiletin and gemcitabine.

Statistical Analysis

The interaction between nobiletin and gemcitabine was determined using a combination index (CI), which was calculated according to the median-effect principle, based on previous reports. The equation for the isobologram was shown as CI = A1/A2 + B1/B2, where A1 and B1 represent the doses of nobiletin and gemcitabine necessary to produce the same effect in combination, and A2 and B2 represent the individual doses of nobiletin and gemcitabine required to inhibit a given level of cell viability, respectively. If CI is <1, then the drugs are considered to act synergistically. If CI is >1 or =1, the drugs act in an antagonistic or additive manner, respectively. Statistical analyses were done by using the software InStat (GraphPad Software, Inc., La Jolla, CA, USA). All the data are presented as mean ± SEM. Experimental data analysis was carried out using one-way ANOVA. A P value < 0.05 was considered statistically significant.

Results

Effects of Nobiletin on Cell Viability and Sphere Formation in Pancreatic Cancer Cells

In initial studies, the effect of nobiletin on cell viability and sphere formation in pancreatic cancer cells were determined. The structure of nobiletin is shown in Figure 1(A). PANC-1 and MIA PaCa-2 cells were treated with nobiletin at different concentrations (10, 120 μM) for 24 hours, 48 hours, and 72 hours, and then analyzed by MTT assay. As shown in Figure 1(B), treatment with nobiletin resulted in decreases in the viability of the cells in a dose-dependent and time-dependent manner. These results agree with previous studies. With increase in time and concentration, the inhibitory effect of nobiletin on the 2 cell lines increased. Under the same conditions, nobiletin had a stronger inhibitory effect on MIA PaCa-2 cells than on PANC-1 cells. After treatment with nobiletin for 72 hours, the cell morphology observed by microscopy is shown in Figure 1(C). In addition, we determined the inhibitory effect of nobiletin on the formation of spheres in PANC-1 and MIA CaPa-2 cells. Due to a longer treatment time for PANC-1 and MIA CaPa-2 cells with nobiletin (14 days), we used lower concentrations of nobiletin (10, 20, 40 μM) for sphere formation assay. As shown in Figure 1(D–E), compared with the control group, nobiletin significantly decreased the size and number of PANC-1 and MIA CaPa-2 spheres in a dose-dependent manner.

Effects of Nobiletin on Invasion and Migration of PANC-1 Cells

The effects of nobiletin on migration of PANC-1 cells was determined by wound-healing assays. Treating with nobiletin at 10-80 μM for 24 hours and 48 hours produced little growth inhibition of PANC-1 cells (cell viable inhibition rate was under 20%). These findings suggest that if wound-healing assays were performed within 48 hours, the effects of nobiletin at 10-80 μM would not be due to cytotoxicity, but instead due to inhibition of cell migration. Thus, we selected 40 and 80 μM for wound-healing assays. As shown in Figure 2 (A–B), treatment with different concentrations of nobiletin for 24 hours and 48 hours, significantly reduced PANC-1 cells moving into the wound. Moreover, we used a transwell assay with and without Matrigel to determine the effects of nobiletin on cell migration and invasion. After treatment with nobiletin for 24 hours, the number of cells that had migrated and invaded is shown in Figure 2 (C–E). Nobiletin reduced the migration and invasion abilities of PANC-1 cells in a dose-dependent manner. In addition, we investigated the effect of nobiletin on the levels of MMP-2 in PANC-1 cells. As shown in Figure 2 (F–G), treatment with nobiletin decreased the protein levels of MMP-2. These results indicate that inhibition of migration and invasion in
PANC-1 cells was associated with downregulation of MMP-2 expression.

**Effect of Nobiletin on the Levels of P-mTOR and P-STAT3 in PANC-1 Cells**

Next, we investigated the possible regulatory mechanisms leading to inhibition of viability, migration, and invasion by nobiletin in PANC-1 cells. STAT3, a critical signaling molecule, has been shown to promote the growth, survival, migration, and attachment of cancer cells. Therefore, we examined the inhibitory effects of nobiletin on STAT3 in PANC-1 cells. Western blot was performed to determine the expression levels of total and p-STAT3 protein. As shown in Figure 3(A and C), nobiletin significantly inhibited the expression of p-STAT3 in a dose-dependent manner. Furthermore, we determined the level of p-mTOR levels in PANC-1 cells. Hyperactivation of mTOR signaling promotes cell proliferation and metabolism that contribute to tumor initiation and progression. Targeting mTOR may provide benefits for the treatment of pancreatic cancer. In the present study, we found that nobiletin strongly decreased the level of p-mTOR at high concentration (Figure 3(A–B)). These results indicated that the effects of nobiletin in pancreatic cancer cells were associated with decreased activities of STAT3 and mTOR. In additional experiments, we determined the effect of knocking down STAT3 or mTOR on nobiletin-induced inhibition of PANC-1 cells. As shown in Figure 3(D), decreases in the expression levels of STAT3 and mTOR were confirmed by Western blotting. Treatment of the cells after STAT3 siRNA transfection with 80 or 120 µM nobiletin resulted in a reduced inhibitory effect on cell viability compared to the cells without STAT3 siRNA transfection (Figure 3(E); \( P < 0.05 \)). Transfection with mTOR siRNA also significantly reduced the inhibitory effect of nobiletin on cell viability (Figure 3(E); \( P < 0.05 \)).

**Nobiletin Enhances the Anti-Cancer Effect of Gemcitabine on PANC-1 Cells**

Since gemcitabine is commonly used in pancreatic cancer treatment, we sought to determine whether nobiletin could sensitize PANC-1 cells to gemcitabine. The viability of PANC-1 cells treated with nobiletin (20, 40, 80 µM) and gemcitabine (0.2 µM) was assessed after 72 hours treatment. As shown in Figure 4(A), compared with gemcitabine treatment alone, a stronger inhibitory effect on viability was observed with nobiletin and gemcitabine used together to treat PANC-1 cells. Moreover, we used the
isobologram to analyze the synergistic effect of nobiletin and gemcitabine. The CI value is shown on the top of the column. PANC-1 cells treated with gemcitabine and nobiletin in combination showed strong synergy (CI = 0.25-0.46). We also determined the influence of knocking down STAT3 through siRNA on the synergistic effect of nobiletin combined with gemcitabine. As shown in Figure 4(B), transfection with STAT3 siRNA greatly reduced the synergy between nobiletin and gemcitabine (CI = 0.9-0.96). This result suggests that STAT3 is important for the synergistic interactions of gemcitabine and nobiletin. In addition, we selected a low concentration of gemcitabine (1 nM) combined with nobiletin (10, 20 µM) for treating PANC-1 cells in the sphere formation assay. As shown in Figure 4(C and D), the combination of nobiletin and gemcitabine decreased the size and number of PANC-1 spheres in a dose-dependent manner.

Effects of Nobiletin and Gemcitabine on the Levels of P-mTOR and P-STAT3
To further investigate the mechanism of nobiletin and gemcitabine in synergistically inhibiting the viability of PANC-1 cells, we determined the levels of p-mTOR and p-STAT3 in the cells.
As shown in Figure 5, treatment with 0.2 µM gemcitabine had a small effect on decreasing the levels of p-STAT3 and p-mTOR in PANC-1 cells. Combining gemcitabine with nobiletin in the treatment showed a stronger effect on decreasing the level of p-STAT3, but showed no inhibitory effect on the level of p-mTOR in PANC-1 cells. These results thus provide evidence that the synergistic effect of gemcitabine and nobiletin on PANC-1 cells was associated with decrease in the levels of p-STAT3.

**Discussion**

We have been interested in developing effective combinations for the treatment of pancreatic cancer. In our continuing search for natural compounds that can enhance the efficacy of chemotherapeutic drugs, nobiletin was found to have a strong combined effect with gemcitabine. Therefore, we further evaluated the effects of nobiletin on migration, invasion and sphere formation in pancreatic cancer cells. We also investigated the mechanisms and molecular targets important for the synergistic effect of nobiletin and gemcitabine. The present study provides important information for our future studies on nobiletin analogs.

Nobiletin has been shown to inhibit proliferation and induce apoptosis in pancreatic cancer cells. In a recent study, Jiang and colleagues found that nobiletin inhibited the growth and metastasis of pancreatic cancer MIA PaCa-2 cells via induction of autophagy and inhibition of the NF-κB signaling pathway. Nobiletin inhibits migration and invasion in osteosarcoma and nasopharyngeal cancer cells. In the present study, we found that nobiletin inhibited migration and invasion...
of PANC-1 cells. To understand the molecular mechanism related to the effects of nobiletin on migration and invasion of pancreatic cancer cells, we examined the expression of proteins associated with migration and invasion. Matrix metalloproteinases (MMPs) play important roles in tumor invasion and metastasis. It is well established that inhibition of MMP gene expression or enzyme activity is an effective way to prevent cancer metastasis. Pharmacological inhibitors of MMP have been used in clinical trial. MMP-2 was most widely studied showing that both gain and loss-of function are associated with the invasive metastatic potential of cancer cells. Our studies showed that nobiletin significantly inhibited the migration and invasion of PANC-1 cells, and these effects were associated with down-regulating the expression of MMP-2.

To explore further the molecular mechanisms of nobiletin on inhibiting pancreatic cancer cells, we determined the effects of nobiletin on STAT3 and mTOR, which have been shown to play an important role in pancreatic cancer cell growth and metastasis. STAT3 is well known to be activated by many trans-membrane growth factor receptors, cytosolic kinases, and the Janus kinases (JAK), which suggest that targeting STAT3 could be a promising way to treat pancreatic cancer. Previous studies have shown that nobiletin effectively inhibited the activation of STAT3. However, the effect of nobiletin on the levels of STAT3 in PANC-1 cells has not been reported. In the present study, we found that nobiletin decreased the level of phosphorylated STAT3.

Clinical study has shown that approximately 15% to 20% of human pancreatic cancers exhibit high levels of active phosphorylated mTOR, and these patients have significantly reduced survival. Many studies indicate that inhibition of mTOR may provide benefits for the treatment of pancreatic cancer. mTOR is one of the downstream proteins of EGFR, and both STAT3 and mTOR can effectively promote cell proliferation, invasion and metastasis in pancreatic cancer cells. mTOR signaling is also involved in the development of resistance to anti-cancer therapies. STAT3 and mTOR activation are also associated with inflammation in pancreatic cancer tissues and may serve as targets for inhibiting cancer-related...
inflammation. Therefore, we examined the effect of nobiletin on mTOR expression in PANC-1 cells, and the result showed that nobiletin had an inhibitory effect on mTOR. Our results suggest that the inhibitory effects of nobiletin on growth, migration and invasion of PANC-1 cells were associated with suppression of STAT3 and mTOR activation. Moreover, the results of our study demonstrated the knocking down of STAT3 and mTOR by siRNA decreased the inhibitory effect of nobiletin on PANC-1 cell viability. These results suggest that the inhibitory effect of nobiletin on PANC-1 cell viability is likely mediated by inhibition of STAT3 and mTOR phosphorylation. Future studies are needed to explore the mechanisms by which nobiletin inhibits STAT3 and mTOR phosphorylation.

Gemcitabine-based chemotherapy is a commonly used treatment for pancreatic cancer. However, chemotherapy with gemcitabine alone has limited success because of the development of drug resistance. Therefore, there is an urgent need for strategies to enhance chemosensitivity to gemcitabine, which would improve the outcome of gemcitabine chemotherapy. Suppression of STAT3 was shown to either inhibit cancer cells or increase the efficacy of chemotherapeutic agents. A growing body of evidence has suggested that the combination of different anticancer agents may produce enhanced efficacy in comparison with the effects produced by each individual agent alone. In the present study, we investigated whether nobiletin could enhance the effect of gemcitabine on PANC-1 cells. Our results showed that nobiletin in combination with gemcitabine synergistically inhibited PANC-1 cell growth, and the combination strongly decreased the level of phosphorylated STAT3. Moreover, we found that knocking down STAT3 through siRNA decreased the synergistic effect of nobiletin and gemcitabine. This result suggests that STAT3 phosphorylation is important for the synergistic interaction between nobiletin and gemcitabine.

Conclusion

In summary, the results of the present study demonstrated that nobiletin had strong inhibitory effects on cell viability, sphere formation, migration and invasion of human pancreatic cancer cells. The results also demonstrated that nobiletin and gemcitabine in combination synergistically inhibited the viability of PANC-1 cells. Mechanistic studies indicate that the inhibition of migration and invasion in PANC-1 cells by nobiletin was associated with downregulation of MMP-2. The inhibitory effect of nobiletin on cell viability was associated with decreases in phosphorylated STAT3 and mTOR. Our study suggests that STAT3/pSTAT3 is important for the synergistic interaction between nobiletin and gemcitabine. The present study provides strong in vitro evidence for the anti-pancreatic cancer activity of nobiletin. Further studies using suitable animal models to examine the in vivo effects of nobiletin alone or in combination with gemcitabine are warranted.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The present study was supported by grants from the Rutgers Cancer Institute of New Jersey (CCSG P30-CA072720), the Department of Education of Guangdong Province (2016KXXTD005, 2017KZDXM084, 2017KSYS010) and the Jiangmen Program for Innovative Research Team (2017TD02). Dr Xi Zheng is the Unilever Chair in Nutrition and Disease Prevention Research at Rutgers University.

ORCID IDs

Xuetao Xu https://orcid.org/0000-0002-6919-948X
Xi Zheng https://orcid.org/0000-0001-7522-631X

References

1. Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. *Mol Cancer*. 2018;17(1):108 (1-15) doi:10.1186/s12934-018-0858-1
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7-34. doi:10.3322/caac.21551
3. van Duinneveldt G, Griffin MDW, Putocki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. *Clin Sci*. 2020;134(16):2091-2115. doi:10.1042/CS20191211
4. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol*. 1997;15(6):2403-2413. doi:10.1200/JCO.1997.15.6.2403
5. Vincent A, Herman J, Schuilk R, Hruhan RH, Goggins M. Pancreatic cancer. *The Lancet*. 2011;378(9791):607-620. doi:10.1016/S0140-6736(10)63207-0
6. de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. *Eur J Pharmacol*. 2014;741(741):8-16. doi:10.1016/j.ejphar.2014.07.041
7. Carr RM, Duma N, McClary-Wheeler AL, et al. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of vismodegib and sirolimus combination. *Pamwaptology*. 2020;20(6):1115-1122. doi:10.1016/j.pamwapt.2020.06.015
8. Kim C, Cho SK, Kapoor S, et al. β-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase. *Mol Cancer*. 2014;53(10):793-806. doi:10.1016/mcc.22035
9. Lee JH, Kim C, Sethi G, Ahn KS. Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. *Oncotarget*. 2015;6(6):6386-6405. doi:10.18632/onco targeted.3443
10. Benavente-García O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer,
cardiovascular, and anti-inflammatory activity. *J Agric Food Chem.* 2008;56(15):6185-6205. doi:10.1021/jf8006568

11. Li S, Lo C-Y, Ho C-T. Hydroxylated polyethoxyflavonones and methylated flavonoids in sweet orange (*Citrus sinensis*) peel. *J Agric Food Chem.* 2006;54(12):4176-4185. doi:10.1021/jf060234n

12. Wu X, Song M, Rakarivatham K, et al. Inhibitory effects of 4’-demethylnobiletin, a metabolite of Nobiletin, on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mouse ears. *J Agric Food Chem.* 2015;63(51):10921-10927. doi:10.1021/acs.jafc.5b05156

13. Wu J-C, Tsai M-L, Lai C-S, et al. Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium sulfate-induced colorectal carcinogenesis through modulating xenobiotic metabolism and ameliorate autophagic defect in ICR mice. *Int J Cancer.* 2018;142(8):1689-1701. doi:10.1002/ijc.31190

14. Goh JXH, Tan LT-H, Goh JK, et al. Nobiletin and derivatives: functional compounds from citrus fruit peel for colon cancer chemoprevention. *Cancers.* 2019;11(6):867(1-34). doi:10.3390/cancers11060867

15. Lai C-S, Ho M-H, Tsai M-L, et al. Suppression of adipogenesis and obesity in high-fat induced mouse model by hydroxylated polyethoxyflavonones. *J Agric Food Chem.* 2013;61(43):10320-10328. doi:10.1021/jf402257t

16. Jiang H, Chen H, Jin C, Mo J, Wang H. Nobiletin flavone inhibits the growth and maturation of human pancreatic cancer cells via induction of autophagy, G0/G1 cell cycle arrest and inhibition of NF-kB signalling pathway. *J Boost.* 2020;25(2):1070-1075.

17. Moon JY, Cho SK. Nobiletin induces protective autophagy accompanied by ER-stress mediated apoptosis in human gastric cancer SNU-16 cells. *Molecules.* 2016;21(7):914(1-13):914. doi:10.3390/molecules21070914

18. Sp N, Kang DY, Kim DH, et al. Nobiletin inhibits CD36-dependent tumor angiogenesis, migration, invasion, and sphere formation through the Cd36/Stat3/NF-Kb signaling axis. *Nutrients.* 2018;10(6):772(1-15). doi:10.3390/nu10060772

19. Zhang Y, Dou H, Li H, He Z, Wu H. The citrus flavonoid nobiletin inhibits proliferation and induces apoptosis in human pancreatic cancer cells in vitro. *Food Sci Biotechnol.* 2014;23(1):225-229. doi:10.1007/s10068-014-0031-6

20. Ma W, Feng S, Yao X, Yuan Z, Liu L, Xie Y. Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells. *Sci Rep.* 2015;5(1-15):18789. doi:10.1038/srep18789

21. Wu X, Song M, Qiu P, et al. Synergistic chemopreventive effects of nobiletin and atorvastatin on colon carcinogenesis. *Carcinogenesis.* 2017;38(4):455-464. doi:10.1093/carcin/bgx018

22. Huang H, He Y, Zhang L, et al. Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells. *Food Funct.* 2018;9(4):2398-2408. doi:10.1039/C7FO01983A

23. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res.* 2010;70(2):440-446. doi:10.1158/0008-5472.CAN-09-1947

24. Yu L, Wu X, Chen M, et al. The effects and mechanism of YK-4-279 in combination with docetaxel on prostate cancer. *Int J Mol Sci.* 2017;14(4):356-366. doi:10.7150/ijms.18382

25. Liu C, Shi J, Li Q, et al. Stat1-Mediated inhibition of FoxM1 enhances gemcitabine sensitivity in pancreatic cancer. *Clin Sci.* 2019;133(5):645-663. doi:10.1042/CS20180816

26. Tian T, Li X, Zhang J. Mtor signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. *Int J Mol Sci.* 2019;20(3):755(1-34). doi:10.3390/ijms20030755

27. Cheng H-I, Hsieh M-J, Yang J-S, et al. Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression. *Oncotarget.* 2016;7(25):35208-35223. doi:10.18632/oncotarget.9106

28. Chien S-Y, Hsieh M-J, Chen C-J, Yang S-F, Chen M-K. Nobiletin inhibits invasion and migration of human nasopharyngeal carcinoma cell lines by involving ERK1/2 and transcriptional inhibition of MMP-2. *Expert Opin Ther Targets.* 2015;19(3):307-320. doi:10.1517/14728222.2014.92875

29. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. *International Journal of Pancreatology.* 1997;21(1):1-12.

30. Guruvayoorappan C, Kuttan G. Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, Erk-1, Erk-2, STAT-1, nm23 and cytokines in lung tissues of C57BL/6 mice. *Immunopharmacol Immunotoxicol.* 2008;30(4):711-727. doi:10.1080/08923970802278276

31. Hu B, Zhang K, Li S, et al. Hicl attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. *Cancer Lett.* 2016;376(2):387-398. doi:10.1016/j.canlet.2016.04.013

32. Morran DC, Wu J, Jamieson NB, et al. Targeting mTOR dependency in pancreatic cancer. *Gut.* 2014;63(9):1481-1489. doi:10.1136/gutjnl-2013-306202

33. Hu B, Cai H, Yang S, Tu J, Huang X, Chen G. Berbamine enhances the efficacy of gefitinib by suppressing STAT3 signaling in pancreatic cancer cells. *Onco Targets Ther.* 2019;12:11437-11451. doi:10.2147/OTT.S223242

34. Fitzgerald TL, Lertpiriyapong K, Cocco L, et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. *Adv Biol Regul.* 2015;59(59):65-81. doi:10.1016/j.jbior.2015.06.003

35. Lankadasari MB, Aparna JS, Mohammed S, et al. Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. *Thermotics.* 2018;8(14):3824-3840. doi:10.7150/thno.25308

36. Wei D, Zhang G, Zhu Z, et al. Nobiletin Inhibits Cell Viability via the SRC/AKT/STAT3/Y1AP1 Pathway in Human Renal Carcinoma Cells. *Front Pharmacol.* 2019;10:690(1-14). doi:10.3389/fphar.2019.00690

37. Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G. Judicious toggling of mTOR activity to combat insulin resistance and cancer: current evidence and perspectives. *Front Pharmacol.* 2016;7(109):395(1-27). doi:10.3389/fphar.2016.00395
38. Garg M, Shanmugam MK, Bhardwaj V, et al. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. *Med Res Rev*. 2020:1-46. doi:10.1002/med.21761

39. Zhang Q-B, Ye R-F, Ye L-Y, Zhang Q-Y, Dai N-G. Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells. *Am J Transl Res*. 2020;12(7):3702-3714.

40. Steele CW, Kaur Gill NA, Jamieson NB, Carter CR. Targeting inflammation in pancreatic cancer: clinical translation. *World J Gastrointest Oncol*. 2016;8(4):380-388. doi:10.4251/wjgo.v8.i4.380

41. Oweida AJ, Mueller AC, Piper M, et al. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. *Cancer Immunol Immunother*. 2020:1-12. doi:10.1007/s00262-020-02701-w

42. Huang H, Cao K, Malik S, et al. Combination of 12-O-tetradecanoylphorbol-13-acetate with diethyldithiocarbamate markedly inhibits pancreatic cancer cell growth in 3D culture and in immunodeficient mice. *Int J Mol Med*. 2015;35(6):1617-1624. doi:10.3892/ijmm.2015.2163